Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21).
Saved in:
| Title: | Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21). |
|---|---|
| Authors: | Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Park K; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea., Koh J; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Park C; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Jung KH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lee J; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Ahn HK; Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea., Lee A; Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, Catholic University, Seoul, Republic of Korea., Sim SH; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea., Kim MH; Division of Medical Oncology and Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Kim JH; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee KE; Department of Hematology and Oncology, Ewha Womans University Hospital, Seoul, Republic of Korea., Park KH; Division of Hemato-Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea., Bae J; Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea., Lee MH; Department of Internal Medicine, Inha University Hospital, Incheon, Republic of Korea., Lim S; Department of Hemato-Oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea., Kim HJ; Division of Oncology and Hematology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea., Lee DW; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Jeong JH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea., Sohn J; Division of Medical Oncology and Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Suh KJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Kim JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Cha YJ; Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Moon J; Lunit, Seoul, Republic of Korea., Ock CY; Lunit, Seoul, Republic of Korea., Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Shin K; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Chae H; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Kim GM; Division of Medical Oncology and Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee KH; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea., Park WY; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea., Park YH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: yhparkhmo@skku.edu., Park IH; Division of Oncology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea. Electronic address: parkih@korea.ac.kr. |
| Corporate Authors: | Korean Cancer Study Group (KCSG) Breast Cancer Committee |
| Source: | ESMO open [ESMO Open] 2025 Oct; Vol. 10 (10), pp. 105804. Date of Electronic Publication: 2025 Sep 24. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
